ArticlePloS one2026
Tool choice matters: Evaluating edgeR vs. DESeq2 for sensitivity, robustness, and cross-study performance.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CEBPG demonstrates oncogene functions and modulates the expression of genes involved in cervical cancer related pathways.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differential gene expression (DGE) analysis is foundational to transcriptomic research, yet tool selection can substantially influence results. This study compares two widely used DGE tools, edgeR and DESeq2, using real and semi-simulated bulk RNA-Seq data sets, mostly from human patients, spanning viral infection, bacterial infection, and fibrotic conditions. We evaluated tool performance across four dimensions: (1) sensitivity to sample size and robustness to outliers; (2) classification performance of uniquely identified gene sets within the discovery dataset; (3) pathway-level concordance of significant DEG sets; and (4) generalizability of tool-specific gene sets across independent studies. First, using Bonferroni-adjusted p-value < 0.05 and absolute log2 fold change greater than 1 (i.e., |log2FC|>1) as significance criteria, repeated subsampling showed that DESeq2 generally identified more Differentially Expressed Genes (DEGs) than edgeR at smaller sample sizes, while the tools became more concordant as sample size increased. Both tools showed similar responses to simulated outliers, with Jaccard similarity decreasing as more swapped samples were introduced. Second, classification models trained on tool-specific genes showed that edgeR achieved higher F1 scores in 9 of 13 contrasts and more frequently reached perfect or near-perfect precision. Third, Hallmark and KEGG pathway enrichment analyses showed that many contrasts retained substantial pathway-level agreement between tools, although selected contrasts still showed tool-specific enriched pathways. Finally, in cross-study validation using four independent SARS-CoV-2 datasets, edgeR-specific genes yielded higher AUC, precision, and recall in held-out datasets, with some test cases achieving perfect separation. Overall, our findings show that DESeq2 may identify more DEGs under stringent thresholds, whereas edgeR often yields more conservative, predictive, and generalizable gene sets. These findings emphasize that DGE tool choice should be guided not only by DEG yield, but also by the downstream reproducibility, predictive value, and biological interpretability of the resulting gene sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.